Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Pfizer reveals the discontinuation of PF-08046044.
The company might have blown Enliven out of the water.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
